Recent news on Valcyte

New Data Show Oral Valcyte(R) (valganciclovir) as Effective as iv ...  -  May 9, 2007
campus med,Valcyte is not approved for use in liver transplantation. The efficacy and safety of Valcyte in other solid organ transplants, such as lung transplant,

New Data Show Oral Valcyte(R) (valganciclovir) as Effective as iv ...  -  May 9, 2007
FinanzNachrichten.de,Valcyte, the oral pro-drug of ganciclovir, is indicated for the prevention of CMV disease in kidney, kidney-pancreas, and heart transplant patients at high

New Data Show Oral Valcyte(R) (valganciclovir) as Effective as iv ...  -  May 9, 2007
Juraforum.de,Valcyte, the oral pro-drug of ganciclovir, is indicated for theprevention of CMV disease in kidney, kidney-pancreas, and hearttransplant patients at high

Dale Guyer, MD, Discusses the Integrative and Molecular Treatment ...  -  Apr 5, 2007
ProHealth's ImmuneSupport.com,While oral agents such as acyclovir, Famvir R and Valtrex R often have good benefit, the recent utilization of Valcyte R [valganciclovir] has been a

Interactive Agencies—Runner-up: OTOi  -  Apr 2, 2007
BtoB Magazine,OTOi created brand guidelines and Web sites for three of Roche's leading brands—CellCept, Valcyte and Zenapax—targeting physicians and patients.

Kent Holtorf, MD, on Treating Chronic Fatigue Syndrome ...  -  Mar 28, 2007
ProHealth's ImmuneSupport.com,For instance, Valcyte is considered a new, novel treatment for CFS, but we have been using it for 4 years, since it was first approved.

BD Biosciences and Roche Collaborate to Advance the Study of Cell ...  -  Mar 8, 2007
Drug Newswire (press release),Medicines discovered at Roche Palo Alto include CellCept(R) (mycophenolate mofetil), Valcyte(R) (valganciclovir) and Naprosyn(R) (naproxen).

BD Biosciences and Roche Collaborate to Advance the Study of Cell ...  -  Feb 27, 2007
PipelineReview.com (press release),Medicines discovered at Roche Palo Alto include CellCept® (mycophenolate mofetil), Valcyte® (valganciclovir) and Naprosyn® (naproxen).

New hope for sufferers of chronic fatigue  -  Feb 4, 2007
Independent Online,Montoya had presented anecdotal data earlier that year at a conference in Barcelona, Spain, which suggested an antiviral drug called Valcyte, made by Swiss

Roche Posts Outstanding Results for 2006  -  Feb 7, 2007
PharmaLive.com (press release),Virology - sales growth driven mainly by Tamiflu Combined sales of Valcyte (valganciclovir) and Cymevene (ganciclovir) continued to show strong growth in

Small trial stirs hope for chronic fatigue patients  -  Jan 16, 2007
The Brunei Times,Montoya had presented anecdotal data earlier that year at a conference in Barcelona, Spain, which suggested an antiviral drug called Valcyte, made by Swiss

Drug to be tested on ME patients  -  Jan 11, 2007
Times Online,...have received a grant for over $1 million (more than £50000 pounds) from Roche Pharmaceutical, which manufactures the drug under the brand name Valcyte,

New therapy for chronic fatigue syndrome to be tested at Stanford  -  Jan 11, 2007
innovations report,Montoya has received a $1.3 million grant from Roche Pharmaceutical, which manufactures the drug under the brand name Valcyte, to conduct a randomized,

Dr. Hans-Joachim Bohm Named President of Roche Palo Alto  -  Dec 11, 2006
Yahoo! News (press release)Medicines discovered at Roche Palo Alto include CellCept® (mycophenolate mofetil), Valcyte® (valganciclovir) and Naprosyn® (naproxen). ...

Dr. Hans-Joachim Bohm Named President of Roche Palo Alto  -  Dec 11, 2006
PharmaLive.com (press release),Medicines discovered at Roche Palo Alto include CellCept(R) (mycophenolate mofetil), Valcyte(R) (valganciclovir) and Naprosyn(R) (naproxen). ...

Options for treating ganciclovir-resistant CMV discussed at IDSA ...  Oct 16, 2006
The current options are the intravenous drugs ganciclovir (Cymevene), foscarnet (Foscavir) and cidofovir (Vistide), and the oral valganciclovir (Valcyte. ... -Aidsmap, Dr. Hans-Joachim Bohm Named President of Roche Palo Alto  -  Dec 11, 2006
Drug Newswire (press release),Medicines discovered at Roche Palo Alto include CellCept(R) (mycophenolate mofetil), Valcyte(R) (valganciclovir) and Naprosyn(R) (naproxen).

Rising rates pinch apartment plan  Aug 14, 2006
Clare's Hospital in Schenectady. Some of her medications are no longer needed, including the antiviral agent Valcyte, which carried a $700-a-month co-pay. ... -Albany Times Union

Operating Profit Falls For Roche Diagnostics  Jul 21, 2006
Combined sales of Valcyte and Cymevene, for prevention of dangerous cytomegalovirus infections, showed strong growth worldwide, advancing 16% to 223 million ... -Inside INdiana Business



Roche Sues to Block Approval of Ranbaxy Version of Valcyte  May 3, 2006
Ranbaxy is seeking approval from the US Food and Drug Administration to sell a version of Valcyte, which contains the key ingredient valganciclovir ... - Bloomberg

Roche sues Ranbaxy over antiviral drug  May 4, 2006
NEW DELHI, MAY 4 : Roche Holding AG has sued Ranbaxy Laboratories Ltd to prevent it from selling the generic version of antiviral drug Valcyte. ... - Financial Express





Roche 2005: Record Sales and Operating Profit  Feb 1, 2006
Valcyte, the market leader for prevention of CMV disease, showed consistent growth throughout the year. A solid double-digit gain ... - PharmaLive.com

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional